Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Resveratrol
- Accession Number
- DB02709 (EXPT02968)
- Type
- Small Molecule
- Groups
- Approved, Experimental, Investigational
- Description
Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as two structural isomers: cis-(Z) and trans-(E), with the trans-isomer shown in the top image. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.
- Structure
Structure for DB02709 (Resveratrol)
- Synonyms
- (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
- (E)-resveratrol
- 3,4',5-trihydroxy-trans-stilbene
- 3,4',5-trihydroxystilbene
- 3,5,4'-trihydroxystilbene
- 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
- trans-resveratrol
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Co-Veratrol Resveratrol (400 mg/mg) + Folic Acid (.8 mg/mg) + Methylcobalamin (5 mg/mg) + Ubiquinol (200 mg/mg) Capsule Oral Home Aide Diganostics, Inc. 2015-08-01 Not applicable US 
Dyzbac Resveratrol (50 mg/1) + Cholecalciferol (500 [iU]/1) + Leucovorin (1 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (1 mg/1) + Pyridoxal Phosphate (12.5 mg/1) + Ubidecarenone (25 mg/1) + Vitamin C (125 mg/1) Tablet Oral Basiem 2015-11-05 2016-01-09 US Mebolex Resveratrol (50 mg/1) + Cholecalciferol (.0125 mg/1) + Leucovorin (1 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (1 mg/1) + Pyridoxal Phosphate (12.5 mg/1) + Ubidecarenone (25 mg/1) + Vitamin C (125 mg/1) Tablet Oral Solubiomix 2015-10-28 2016-01-09 US Medi-10 Resveratrol (83 mg/1) + Acetylcysteine (200 mg/1) + Cholecalciferol (1000 [iU]/1) + Chromium picolinate (1 mg/1) + Levomefolate calcium (2.5 mg/1) + Lipoic Acid (200 mg/1) + Methylcobalamin (2.5 mg/1) + Nicotinamide (10 mg/1) + Pyridoxal Phosphate (20 mg/1) + Ubidecarenone (16 mg/1) Capsule Oral Medicap Laboratories Inc. 2015-05-01 2016-01-15 US - Categories
- Analgesics
- Analgesics, Non-Narcotic
- Angiogenesis Inhibitors
- Anti-Inflammatory Agents
- Anticarcinogenic Agents
- Antimutagenic Agents
- Antineoplastic Agents, Phytogenic
- Antioxidants
- Antiplatelet agents
- Antirheumatic Agents
- Benzene Derivatives
- Benzylidene Compounds
- Central Nervous System Agents
- COX-1 Inhibitors
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Hematologic Agents
- Peripheral Nervous System Agents
- Phenols
- Protective Agents
- Ribonucleotide Reductases, antagonists & inhibitors
- Sensory System Agents
- Vasodilating Agents
- UNII
- Q369O8926L
- CAS number
- 501-36-0
- Weight
- Average: 228.2433
Monoisotopic: 228.07864425 - Chemical Formula
- C14H12O3
- InChI Key
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N
- InChI
- InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
- IUPAC Name
- 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
- SMILES
- OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
Pharmacology
- Indication
Being investigated for the treatment of Herpes labialis infections (cold sores).
- Pharmacodynamics
Resveratrol, a phytoalexin, has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, reversible manner, although this is only one of its many pharmaceutical properties. In some countries where there is higher consumption of red wine, there appears to be a lower incidence of heart disease. Other benefits of resveratrol include its anti-inflammatory and antioxidant effects. In preclinical studies, Resveratrol has been found to have potential anticancer properties.
- Mechanism of action
Resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914].
- Absorption
High absorption but very low bioavailability.
- Volume of distribution
- Not Available
- Protein binding
Strong affinity towards protein binding.
- Metabolism
Hepatic. Rapidly metabolized and excreted.
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Resveratrol. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Resveratrol is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Resveratrol is combined with 5-androstenedione. Experimental, Illicit Abciximab Resveratrol may increase the anticoagulant activities of Abciximab. Approved Abiraterone The serum concentration of Resveratrol can be increased when it is combined with Abiraterone. Approved Acebutolol Resveratrol may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Resveratrol is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Resveratrol is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Resveratrol may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetaminophen The risk or severity of adverse effects can be increased when Resveratrol is combined with Acetaminophen. Approved Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Resveratrol. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Resveratrol. Experimental Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Resveratrol. Approved Alaproclate Alaproclate may increase the antiplatelet activities of Resveratrol. Experimental Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Resveratrol. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Resveratrol is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid. Approved Aliskiren Resveratrol may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Resveratrol. Experimental Aloxiprin The risk or severity of adverse effects can be increased when Resveratrol is combined with Aloxiprin. Experimental Alprenolol Resveratrol may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Resveratrol. Approved, Investigational Alteplase Resveratrol may increase the anticoagulant activities of Alteplase. Approved Amcinonide The risk or severity of adverse effects can be increased when Resveratrol is combined with Amcinonide. Approved Amikacin Resveratrol may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Investigational, Vet Approved Amiloride Resveratrol may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Aminosalicylic Acid. Approved Amiodarone Resveratrol may decrease the antihypertensive activities of Amiodarone. Approved, Investigational Anagrelide Resveratrol may increase the anticoagulant activities of Anagrelide. Approved Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Resveratrol. Approved, Investigational, Withdrawn Ancrod Resveratrol may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Resveratrol. Investigational Androstenedione The risk or severity of adverse effects can be increased when Resveratrol is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Resveratrol is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Resveratrol is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Resveratrol. Investigational Anistreplase Resveratrol may increase the anticoagulant activities of Anistreplase. Approved Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol. Approved, Investigational Antithrombin III human Resveratrol may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Resveratrol is combined with Antrafenine. Approved Apixaban The risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Resveratrol. Investigational Apramycin Resveratrol may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Resveratrol. Approved, Investigational Arbekacin Resveratrol may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Resveratrol may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Resveratrol may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Resveratrol may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Resveratrol may decrease the antihypertensive activities of Asenapine. Approved Astaxanthin Resveratrol may increase the anticoagulant activities of Astaxanthin. Investigational Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Resveratrol. Approved, Investigational, Withdrawn Atamestane The risk or severity of adverse effects can be increased when Resveratrol is combined with Atamestane. Investigational Atenolol Resveratrol may decrease the antihypertensive activities of Atenolol. Approved Atorvastatin The risk or severity of adverse effects can be increased when Resveratrol is combined with Atorvastatin. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Resveratrol. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol. Approved Azficel-T The risk or severity of adverse effects can be increased when Resveratrol is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol. Approved, Investigational Azithromycin The metabolism of Resveratrol can be decreased when combined with Azithromycin. Approved Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Resveratrol. Investigational Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Resveratrol. Approved, Investigational Batroxobin Resveratrol may increase the anticoagulant activities of Batroxobin. Experimental Bazedoxifene Resveratrol may increase the thrombogenic activities of Bazedoxifene. Approved, Investigational Becaplermin Resveratrol may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Resveratrol is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Resveratrol may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Resveratrol may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Bemiparin Resveratrol may increase the anticoagulant activities of Bemiparin. Approved, Investigational Benazepril The risk or severity of adverse effects can be increased when Resveratrol is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Resveratrol. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Resveratrol. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Resveratrol. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Resveratrol. Approved Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Resveratrol. Approved Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Resveratrol. Investigational Betamethasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Betamethasone. Approved, Vet Approved Betaxolol Resveratrol may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Resveratrol. Approved, Investigational Bevacizumab Bevacizumab may increase the cardiotoxic activities of Resveratrol. Approved, Investigational Bevantolol Resveratrol may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Resveratrol. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Resveratrol. Approved, Investigational Bisoprolol Resveratrol may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Resveratrol may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Resveratrol may decrease the antihypertensive activities of Bopindolol. Approved Bortezomib The metabolism of Resveratrol can be decreased when combined with Bortezomib. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Resveratrol. Approved Brinase Resveratrol may increase the anticoagulant activities of Brinase. Experimental Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Resveratrol. Approved, Investigational Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Resveratrol. Investigational Bucindolol Resveratrol may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Resveratrol is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Resveratrol is combined with Bufexamac. Approved, Experimental Buflomedil Resveratrol may increase the antiplatelet activities of Buflomedil. Experimental Bufuralol Resveratrol may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Resveratrol. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Resveratrol. Approved Bupranolol Resveratrol may decrease the antihypertensive activities of Bupranolol. Approved Butylphthalide Resveratrol may increase the antiplatelet activities of Butylphthalide. Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Resveratrol. Approved Caffeine The metabolism of Resveratrol can be decreased when combined with Caffeine. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Resveratrol. Approved Candoxatril The risk or severity of adverse effects can be increased when Resveratrol is combined with Candoxatril. Experimental Cangrelor Resveratrol may increase the anticoagulant activities of Cangrelor. Approved Caplacizumab Resveratrol may increase the anticoagulant activities of Caplacizumab. Investigational Capsaicin The risk or severity of adverse effects can be increased when Resveratrol is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Resveratrol is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Resveratrol. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Resveratrol. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol. Approved, Vet Approved, Withdrawn Carteolol Resveratrol may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Resveratrol may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Resveratrol. Approved, Investigational Celiprolol Resveratrol may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Resveratrol. Approved, Withdrawn Certoparin Resveratrol may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol. Approved, Vet Approved Chlorotrianisene Resveratrol may increase the thrombogenic activities of Chlorotrianisene. Investigational, Withdrawn Chlorphenesin The risk or severity of adverse effects can be increased when Resveratrol is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Resveratrol. Approved Ciclesonide The risk or severity of adverse effects can be increased when Resveratrol is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Cilazapril. Approved Cilostazol Resveratrol may increase the anticoagulant activities of Cilostazol. Approved, Investigational Cimicoxib The risk or severity of adverse effects can be increased when Resveratrol is combined with Cimicoxib. Investigational Cinoxacin Resveratrol may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin Resveratrol may increase the neuroexcitatory activities of Ciprofloxacin. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when Resveratrol is combined with Cisplatin. Approved Citalopram The metabolism of Resveratrol can be decreased when combined with Citalopram. Approved Citric Acid Resveratrol may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clobetasol The risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Resveratrol. Approved Clopidogrel Resveratrol may increase the anticoagulant activities of Clopidogrel. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Resveratrol. Vet Approved Cloranolol Resveratrol may decrease the antihypertensive activities of Cloranolol. Experimental Cloricromen Resveratrol may increase the anticoagulant activities of Cloricromen. Experimental Clorindione Resveratrol may increase the anticoagulant activities of Clorindione. Experimental Clotrimazole The metabolism of Resveratrol can be decreased when combined with Clotrimazole. Approved, Vet Approved Colesevelam Colesevelam can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Resveratrol is combined with Collagenase clostridium histolyticum. Approved, Investigational Conjugated estrogens Resveratrol may increase the thrombogenic activities of Conjugated estrogens. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Resveratrol is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Resveratrol is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Resveratrol is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Resveratrol. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Resveratrol. Experimental Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Resveratrol. Approved, Investigational Cyclosporine Resveratrol may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Resveratrol. Experimental Cyproterone acetate The serum concentration of Resveratrol can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabigatran etexilate Resveratrol may increase the anticoagulant activities of Dabigatran etexilate. Approved Daidzein Resveratrol may increase the thrombogenic activities of Daidzein. Experimental Dalteparin Resveratrol may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Resveratrol may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Dapoxetine Dapoxetine may increase the antiplatelet activities of Resveratrol. Investigational Darexaban Resveratrol may increase the anticoagulant activities of Darexaban. Investigational Dasatinib Dasatinib may increase the anticoagulant activities of Resveratrol. Approved, Investigational Deferasirox The risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox. Approved, Investigational Defibrotide Resveratrol may increase the anticoagulant activities of Defibrotide. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Resveratrol is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Delapril. Experimental Deoxycholic Acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic Acid. Approved Dersalazine The risk or severity of adverse effects can be increased when Resveratrol is combined with Dersalazine. Investigational Desipramine Resveratrol may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Resveratrol may increase the anticoagulant activities of Desirudin. Approved Deslanoside Deslanoside may decrease the cardiotoxic activities of Resveratrol. Approved Desmopressin The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin. Approved Desmoteplase Resveratrol may increase the anticoagulant activities of Desmoteplase. Investigational Desonide The risk or severity of adverse effects can be increased when Resveratrol is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Desvenlafaxine Desvenlafaxine may increase the antiplatelet activities of Resveratrol. Approved, Investigational Dexamethasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Resveratrol is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Resveratrol. Approved, Investigational Dextran Resveratrol may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin Resveratrol may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Resveratrol is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Resveratrol. Approved, Vet Approved Dicoumarol Resveratrol may increase the anticoagulant activities of Dicoumarol. Approved Dienestrol Resveratrol may increase the thrombogenic activities of Dienestrol. Approved, Investigational Diethylstilbestrol Resveratrol may increase the thrombogenic activities of Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Resveratrol. Experimental Diflorasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Resveratrol. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Resveratrol is combined with Difluprednate. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Resveratrol. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Resveratrol. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Resveratrol. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Resveratrol. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Resveratrol. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Resveratrol. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Resveratrol. Approved, Investigational Dihydrostreptomycin Resveratrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Resveratrol. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Resveratrol. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Resveratrol. Approved Diphenadione Resveratrol may increase the anticoagulant activities of Diphenadione. Experimental Dipyridamole Resveratrol may increase the anticoagulant activities of Dipyridamole. Approved Ditazole Resveratrol may increase the anticoagulant activities of Ditazole. Approved, Withdrawn Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol. Approved, Investigational Dosulepin The metabolism of Resveratrol can be decreased when combined with Dosulepin. Approved Drospirenone Resveratrol may increase the hyperkalemic activities of Drospirenone. Approved Drotrecogin alfa Resveratrol may increase the anticoagulant activities of Drotrecogin alfa. Approved, Investigational, Withdrawn Droxicam The risk or severity of adverse effects can be increased when Resveratrol is combined with Droxicam. Withdrawn Duloxetine Duloxetine may increase the antiplatelet activities of Resveratrol. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Resveratrol. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Resveratrol. Investigational Edetic Acid Resveratrol may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Resveratrol may increase the anticoagulant activities of Edoxaban. Approved Enalapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Resveratrol is combined with Enalaprilat. Approved Enoxacin Resveratrol may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Resveratrol may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Resveratrol. Experimental Epanolol Resveratrol may decrease the antihypertensive activities of Epanolol. Experimental Epimestrol Resveratrol may increase the thrombogenic activities of Epimestrol. Experimental Epinastine Epinastine may increase the antiplatelet activities of Resveratrol. Approved, Investigational Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Resveratrol. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Resveratrol. Experimental Eplerenone Resveratrol may decrease the antihypertensive activities of Eplerenone. Approved Eplivanserin Resveratrol may increase the anticoagulant activities of Eplivanserin. Investigational eplivanserine Resveratrol may increase the anticoagulant activities of eplivanserine. Investigational Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Resveratrol. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol. Approved Eptifibatide Resveratrol may increase the anticoagulant activities of Eptifibatide. Approved, Investigational Equilenin The risk or severity of adverse effects can be increased when Resveratrol is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Resveratrol is combined with Equilin. Approved Equol Resveratrol may increase the thrombogenic activities of Equol. Investigational Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Resveratrol. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Resveratrol. Approved Esatenolol Resveratrol may decrease the antihypertensive activities of Esatenolol. Experimental Escitalopram Escitalopram may increase the antiplatelet activities of Resveratrol. Approved, Investigational Esmolol Resveratrol may decrease the antihypertensive activities of Esmolol. Approved Estradiol Resveratrol may increase the thrombogenic activities of Estradiol. Approved, Investigational, Vet Approved Estradiol acetate Resveratrol may increase the thrombogenic activities of Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate Resveratrol may increase the thrombogenic activities of Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate Resveratrol may increase the thrombogenic activities of Estradiol valerate. Approved, Investigational, Vet Approved Estriol Resveratrol may increase the thrombogenic activities of Estriol. Approved, Investigational, Vet Approved Estrogens, esterified Resveratrol may increase the thrombogenic activities of Estrogens, esterified. Approved Estrone The risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Resveratrol. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Resveratrol. Experimental Ethinyl Estradiol Resveratrol may increase the thrombogenic activities of Ethinyl Estradiol. Approved Ethyl biscoumacetate Resveratrol may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Resveratrol. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Resveratrol. Approved, Investigational Etoperidone Etoperidone may increase the antiplatelet activities of Resveratrol. Withdrawn Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Resveratrol. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Resveratrol. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Resveratrol. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Resveratrol. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Resveratrol. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Resveratrol. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Resveratrol. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Resveratrol. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Resveratrol. Experimental Fibrinolysin Resveratrol may increase the anticoagulant activities of Fibrinolysin. Investigational Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Resveratrol. Approved, Investigational Fish oil The risk or severity of adverse effects can be increased when Resveratrol is combined with Fish oil. Approved, Nutraceutical Fleroxacin Resveratrol may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Resveratrol. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Resveratrol is combined with Fludrocortisone. Approved, Investigational Fluindione Resveratrol may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Resveratrol may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Resveratrol is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Resveratrol. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Resveratrol. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluorometholone. Approved, Investigational Fluoxetine Fluoxetine may increase the antiplatelet activities of Resveratrol. Approved, Vet Approved Fluprednidene The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Resveratrol. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Resveratrol is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone propionate. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Resveratrol. Approved Fluvoxamine The metabolism of Resveratrol can be decreased when combined with Fluvoxamine. Approved, Investigational Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Resveratrol. Approved, Nutraceutical, Vet Approved Fondaparinux Resveratrol may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Resveratrol may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol. Experimental Formestane The risk or severity of adverse effects can be increased when Resveratrol is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Resveratrol is combined with Fosinopril. Approved Framycetin Resveratrol may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Resveratrol. Approved, Vet Approved Gabexate Resveratrol may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Resveratrol may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Resveratrol may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Resveratrol. Approved, Withdrawn Gemifloxacin Resveratrol may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Resveratrol may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Genistein Resveratrol may increase the thrombogenic activities of Genistein. Investigational Gentamicin Resveratrol may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Resveratrol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when Resveratrol is combined with Ginseng. Approved, Investigational, Nutraceutical Gitoformate Gitoformate may decrease the cardiotoxic activities of Resveratrol. Experimental Glucosamine Glucosamine may increase the antiplatelet activities of Resveratrol. Approved, Investigational Grepafloxacin Resveratrol may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Resveratrol. Experimental Halcinonide The risk or severity of adverse effects can be increased when Resveratrol is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Resveratrol is combined with HE3286. Investigational Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Resveratrol is combined with Hemoglobin crosfumaril. Experimental Heparin Resveratrol may increase the anticoagulant activities of Heparin. Approved, Investigational Hexestrol Resveratrol may increase the thrombogenic activities of Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Resveratrol. Investigational Hydralazine Resveratrol may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Resveratrol. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol. Approved, Investigational Hydroxytyrosol Resveratrol may increase the antiplatelet activities of Hydroxytyrosol. Investigational Hygromycin B Resveratrol may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate. Approved, Investigational Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Resveratrol. Approved Ibudilast Resveratrol may increase the antiplatelet activities of Ibudilast. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Resveratrol. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Resveratrol. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Resveratrol. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Resveratrol is combined with Icosapent. Approved, Nutraceutical Icosapent ethyl Resveratrol may increase the antiplatelet activities of Icosapent ethyl. Approved, Investigational, Nutraceutical Idraparinux Resveratrol may increase the anticoagulant activities of Idraparinux. Investigational Ifenprodil Resveratrol may increase the antiplatelet activities of Ifenprodil. Approved, Investigational, Withdrawn Ifetroban Resveratrol may increase the antiplatelet activities of Ifetroban. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Resveratrol. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Resveratrol. Experimental Indalpine Indalpine may increase the antiplatelet activities of Resveratrol. Investigational, Withdrawn Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol. Approved Indenolol Resveratrol may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Resveratrol. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Resveratrol. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol. Approved, Investigational Isepamicin Resveratrol may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Resveratrol. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Resveratrol is combined with Istaroxime. Investigational Kanamycin Resveratrol may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Resveratrol. Experimental Ketanserin Resveratrol may increase the antiplatelet activities of Ketanserin. Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Resveratrol. Approved Labetalol Resveratrol may decrease the antihypertensive activities of Labetalol. Approved Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Resveratrol. Experimental Landiolol Resveratrol may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Resveratrol. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Resveratrol. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Resveratrol. Approved, Investigational Lepirudin Resveratrol may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Resveratrol may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol Resveratrol may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Resveratrol may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Resveratrol may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Levomilnacipran Levomilnacipran may increase the antiplatelet activities of Resveratrol. Approved, Investigational Lidocaine The metabolism of Resveratrol can be decreased when combined with Lidocaine. Approved, Vet Approved Limaprost Limaprost may increase the antiplatelet activities of Resveratrol. Approved, Investigational Linsidomine Resveratrol may increase the antiplatelet activities of Linsidomine. Experimental Lisinopril The risk or severity of adverse effects can be increased when Resveratrol is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Resveratrol. Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Resveratrol. Approved, Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Resveratrol. Approved Lobeglitazone The metabolism of Resveratrol can be decreased when combined with Lobeglitazone. Approved, Investigational Lomefloxacin Resveratrol may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Resveratrol. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol. Approved Loteprednol The risk or severity of adverse effects can be increased when Resveratrol is combined with Loteprednol. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Resveratrol. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Resveratrol. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Resveratrol. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Resveratrol. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Resveratrol. Vet Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Resveratrol. Illicit, Investigational, Withdrawn Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Resveratrol is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Resveratrol is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol. Approved Melagatran Resveratrol may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol. Approved, Vet Approved Mepindolol Resveratrol may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Resveratrol. Approved Mestranol Resveratrol may increase the thrombogenic activities of Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Resveratrol. Approved, Investigational, Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Resveratrol. Experimental Methallenestril Resveratrol may increase the thrombogenic activities of Methallenestril. Experimental Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Resveratrol. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Resveratrol is combined with Methyl salicylate. Approved, Vet Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Resveratrol. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Methylprednisolone. Approved, Vet Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Resveratrol. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Resveratrol. Experimental Metipranolol Resveratrol may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol. Approved Metoprolol Resveratrol may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Resveratrol. Experimental Mexiletine The metabolism of Resveratrol can be decreased when combined with Mexiletine. Approved, Investigational Micronomicin Resveratrol may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Midostaurin The metabolism of Resveratrol can be decreased when combined with Midostaurin. Approved, Investigational Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Resveratrol. Approved, Experimental Milnacipran Milnacipran may increase the antiplatelet activities of Resveratrol. Approved, Investigational Milrinone Milrinone may increase the antiplatelet activities of Resveratrol. Approved Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Resveratrol. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Resveratrol. Investigational Moexipril The risk or severity of adverse effects can be increased when Resveratrol is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Resveratrol. Experimental Mometasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Resveratrol. Approved Moxestrol Resveratrol may increase the thrombogenic activities of Moxestrol. Experimental Moxifloxacin Resveratrol may increase the neuroexcitatory activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Resveratrol. Approved Nadolol Resveratrol may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Resveratrol may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Resveratrol. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Resveratrol. Approved Naftopidil Resveratrol may increase the antiplatelet activities of Naftopidil. Investigational Nalidixic Acid Resveratrol may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Resveratrol. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 1022. Investigational Neamine Resveratrol may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Resveratrol may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nefazodone Nefazodone may increase the antiplatelet activities of Resveratrol. Approved, Withdrawn Nemonoxacin Resveratrol may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin Resveratrol may decrease the excretion rate of Neomycin which could result in a higher serum level. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Resveratrol. Approved, Investigational Netilmicin Resveratrol may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nevirapine The metabolism of Resveratrol can be decreased when combined with Nevirapine. Approved Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Resveratrol. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Resveratrol. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid. Approved Nimesulide The risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Resveratrol. Investigational Norfloxacin Resveratrol may increase the neuroexcitatory activities of Norfloxacin. Approved Obinutuzumab The risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab. Approved, Investigational Ofloxacin Resveratrol may increase the neuroexcitatory activities of Ofloxacin. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Resveratrol. Experimental, Investigational Oleoyl-estrone The risk or severity of adverse effects can be increased when Resveratrol is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Resveratrol. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Resveratrol is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Resveratrol is combined with Omapatrilat. Investigational Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Resveratrol. Approved, Nutraceutical Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Resveratrol. Vet Approved Osimertinib The serum concentration of Resveratrol can be decreased when it is combined with Osimertinib. Approved Otamixaban Resveratrol may increase the anticoagulant activities of Otamixaban. Investigational Ouabain Ouabain may decrease the cardiotoxic activities of Resveratrol. Approved Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol. Approved Oxolinic acid Resveratrol may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Resveratrol may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Resveratrol. Approved, Withdrawn Ozagrel Resveratrol may increase the anticoagulant activities of Ozagrel. Investigational Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol. Approved, Vet Approved Palmidrol The risk or severity of adverse effects can be increased when Palmidrol is combined with Resveratrol. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Resveratrol is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Resveratrol is combined with Parecoxib. Approved Parnaparin Resveratrol may increase the anticoagulant activities of Parnaparin. Approved, Investigational Paromomycin Resveratrol may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Paroxetine Paroxetine may increase the antiplatelet activities of Resveratrol. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Resveratrol. Approved, Investigational Pazufloxacin Resveratrol may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Resveratrol may increase the neuroexcitatory activities of Pefloxacin. Approved Peginterferon alfa-2b The serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b. Approved Penbutolol Resveratrol may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Resveratrol may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol. Approved Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Resveratrol. Approved, Investigational Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Resveratrol. Approved, Investigational, Vet Approved, Withdrawn Perindopril The risk or severity of adverse effects can be increased when Resveratrol is combined with Perindopril. Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Resveratrol. Experimental Phenindione Resveratrol may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Resveratrol may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Resveratrol is combined with Phenyl aminosalicylate. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol. Approved, Vet Approved Picotamide Resveratrol may increase the anticoagulant activities of Picotamide. Experimental Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol. Approved, Investigational Pindolol Resveratrol may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Resveratrol may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Resveratrol. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Resveratrol. Approved, Investigational Piromidic acid Resveratrol may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Resveratrol. Experimental Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Resveratrol. Approved Pitolisant The risk or severity of adverse effects can be increased when Resveratrol is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Resveratrol may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Resveratrol may decrease the excretion rate of Plazomicin which could result in a higher serum level. Investigational Polyestradiol phosphate Resveratrol may increase the thrombogenic activities of Polyestradiol phosphate. Approved Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Resveratrol. Approved Pomalidomide The risk or severity of adverse effects can be increased when Resveratrol is combined with Pomalidomide. Approved Potassium Citrate Resveratrol may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Resveratrol may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Resveratrol. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Resveratrol. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone sulfate. Investigational Prasugrel Resveratrol may increase the anticoagulant activities of Prasugrel. Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Resveratrol. Approved Prednicarbate The risk or severity of adverse effects can be increased when Resveratrol is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Resveratrol can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Resveratrol. Experimental Promestriene Resveratrol may increase the thrombogenic activities of Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Resveratrol. Approved, Investigational Propafenone Resveratrol may decrease the antihypertensive activities of Propafenone. Approved Propranolol Resveratrol may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Resveratrol. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Resveratrol. Experimental Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Resveratrol. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Resveratrol. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Resveratrol. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Resveratrol. Vet Approved Protein C Resveratrol may increase the anticoagulant activities of Protein C. Approved Protein S human Resveratrol may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Resveratrol may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Resveratrol may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Resveratrol. Investigational Puromycin Resveratrol may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Quinapril. Approved, Investigational Quinestrol Resveratrol may increase the thrombogenic activities of Quinestrol. Approved Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol. Approved Ramatroban Resveratrol may increase the antiplatelet activities of Ramatroban. Investigational Ramipril The risk or severity of adverse effects can be increased when Resveratrol is combined with Ramipril. Approved Relcovaptan Resveratrol may increase the antiplatelet activities of Relcovaptan. Investigational Rescinnamine The risk or severity of adverse effects can be increased when Resveratrol is combined with Rescinnamine. Approved Reteplase Resveratrol may increase the anticoagulant activities of Reteplase. Approved, Investigational Reviparin Resveratrol may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Resveratrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Ridogrel Ridogrel may increase the antiplatelet activities of Resveratrol. Approved Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Resveratrol. Approved Rimexolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate. Approved, Investigational Rivaroxaban Resveratrol may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Resveratrol. Approved, Investigational, Withdrawn Ropinirole The metabolism of Resveratrol can be decreased when combined with Ropinirole. Approved, Investigational Rosiglitazone Resveratrol may increase the anticoagulant activities of Rosiglitazone. Approved, Investigational Rosoxacin Resveratrol may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Resveratrol. Approved Rucaparib The metabolism of Resveratrol can be decreased when combined with Rucaparib. Approved, Investigational Rufloxacin Resveratrol may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Resveratrol. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Resveratrol. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Resveratrol. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Resveratrol. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Resveratrol. Approved, Investigational Sarpogrelate Resveratrol may increase the anticoagulant activities of Sarpogrelate. Investigational Saruplase Resveratrol may increase the anticoagulant activities of Saruplase. Experimental Secoisolariciresinol Resveratrol may increase the thrombogenic activities of Secoisolariciresinol. Investigational Selexipag Resveratrol may increase the anticoagulant activities of Selexipag. Approved Seliciclib The risk or severity of adverse effects can be increased when Resveratrol is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Resveratrol. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Resveratrol. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Resveratrol. Investigational Sertraline Sertraline may increase the antiplatelet activities of Resveratrol. Approved Sevoflurane Sevoflurane may increase the antiplatelet activities of Resveratrol. Approved, Vet Approved Simeprevir The metabolism of Resveratrol can be decreased when combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Resveratrol. Approved Sisomicin Resveratrol may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Resveratrol may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium Citrate Resveratrol may increase the anticoagulant activities of Sodium Citrate. Approved, Investigational Sodium phosphate Sodium phosphate may increase the nephrotoxic activities of Resveratrol. Approved Sotalol Resveratrol may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin Resveratrol may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Spirapril. Approved Spironolactone Resveratrol may decrease the antihypertensive activities of Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Resveratrol. Investigational Streptokinase Resveratrol may increase the anticoagulant activities of Streptokinase. Approved, Investigational Streptomycin Resveratrol may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Resveratrol. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Resveratrol. Approved, Investigational Sulodexide Resveratrol may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Resveratrol. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Resveratrol. Experimental Synthetic Conjugated Estrogens, A Resveratrol may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B Resveratrol may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B. Approved Tacrolimus Resveratrol may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Resveratrol. Approved Talinolol Resveratrol may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Resveratrol. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Resveratrol. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Resveratrol. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol. Approved, Investigational Temafloxacin Resveratrol may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Temocapril. Experimental, Investigational Tenecteplase Resveratrol may increase the anticoagulant activities of Tenecteplase. Approved Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Resveratrol. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Resveratrol is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Resveratrol. Vet Approved Terbutaline Resveratrol may decrease the antihypertensive activities of Terbutaline. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Resveratrol. Experimental Teriflunomide The serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide. Approved Tertatolol Resveratrol may decrease the antihypertensive activities of Tertatolol. Experimental Tesmilifene Resveratrol may increase the antiplatelet activities of Tesmilifene. Investigational Theophylline The metabolism of Resveratrol can be decreased when combined with Theophylline. Approved Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol. Approved Tibolone Resveratrol may increase the thrombogenic activities of Tibolone. Approved, Investigational Ticagrelor Resveratrol may increase the anticoagulant activities of Ticagrelor. Approved Ticlopidine The metabolism of Resveratrol can be decreased when combined with Ticlopidine. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Resveratrol may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Resveratrol. Investigational Tinzaparin Resveratrol may increase the anticoagulant activities of Tinzaparin. Approved Tioclomarol Resveratrol may increase the anticoagulant activities of Tioclomarol. Experimental Tipranavir Tipranavir may increase the antiplatelet activities of Resveratrol. Approved, Investigational Tirofiban Resveratrol may increase the anticoagulant activities of Tirofiban. Approved Tixocortol The risk or severity of adverse effects can be increased when Resveratrol is combined with Tixocortol. Approved, Withdrawn Tobramycin Resveratrol may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Resveratrol. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Resveratrol. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Resveratrol. Approved Tositumomab The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab. Approved, Investigational Trandolapril The risk or severity of adverse effects can be increased when Resveratrol is combined with Trandolapril. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Resveratrol. Approved, Investigational Trapidil Resveratrol may increase the antiplatelet activities of Trapidil. Approved Trastuzumab Trastuzumab may increase the cardiotoxic activities of Resveratrol. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Resveratrol is combined with Triamcinolone. Approved, Vet Approved Triamterene Resveratrol may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Resveratrol. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol. Approved, Vet Approved Triflusal Resveratrol may increase the anticoagulant activities of Triflusal. Approved, Investigational Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Resveratrol. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Resveratrol is combined with Trolamine salicylate. Approved Trovafloxacin Resveratrol may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Resveratrol may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Resveratrol is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Resveratrol. Approved, Investigational Urokinase Resveratrol may increase the anticoagulant activities of Urokinase. Approved, Investigational, Withdrawn Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Resveratrol. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Resveratrol. Approved Vemurafenib The serum concentration of Resveratrol can be increased when it is combined with Vemurafenib. Approved Venlafaxine Venlafaxine may increase the antiplatelet activities of Resveratrol. Approved Vitamin E Vitamin E may increase the antiplatelet activities of Resveratrol. Approved, Nutraceutical, Vet Approved Vorapaxar Resveratrol may increase the anticoagulant activities of Vorapaxar. Approved Warfarin Resveratrol may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Resveratrol may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Resveratrol. Approved, Investigational Zeranol Resveratrol may increase the thrombogenic activities of Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Resveratrol. Approved, Investigational, Withdrawn Zimelidine Zimelidine may increase the antiplatelet activities of Resveratrol. Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Resveratrol is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Resveratrol is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Resveratrol. Withdrawn Zucapsaicin The metabolism of Resveratrol can be decreased when combined with Zucapsaicin. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Philippe Jeandet, Roger Bessis, Marielle Adrian, Jean-Claude Yvin, Jean-Marie Joubert, "Use of aluminium chloride as a resveratrol synthesis elicitor." U.S. Patent US6080701, issued August, 1991.
US6080701- General References
- Farina A, Ferranti C, Marra C: An improved synthesis of resveratrol. Nat Prod Res. 2006 Mar;20(3):247-52. [PubMed:16401555]
- Renaud S, Ruf JC: The French paradox: vegetables or wine. Circulation. 1994 Dec;90(6):3118-9. [PubMed:7994864]
- Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB: An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002 Jan 30;50(3):431-5. [PubMed:11804508]
- Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J, van Breemen RB: Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003 Sep 24;51(20):5867-70. [PubMed:13129286]
- Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27. [PubMed:15333514]
- Csaki C, Keshishzadeh N, Fischer K, Shakibaei M: Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol. 2008 Feb 1;75(3):677-87. Epub 2007 Sep 18. [PubMed:17959154]
- Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL: Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. [PubMed:10551373]
- N' soukpoe-Kossi CN, St-Louis C, Beauregard M, Subirade M, Carpentier R, Hotchandani S, Tajmir-Riahi HA: Resveratrol binding to human serum albumin. J Biomol Struct Dyn. 2006 Dec;24(3):277-83. [PubMed:17054386]
- External Links
- Human Metabolome Database
- HMDB0003747
- KEGG Compound
- C03582
- PubChem Compound
- 445154
- PubChem Substance
- 46504705
- ChemSpider
- 392875
- BindingDB
- 23926
- ChEBI
- 45713
- ChEMBL
- CHEMBL165
- Therapeutic Targets Database
- DNC001205
- PharmGKB
- PA165291838
- HET
- STL
- Wikipedia
- Resveratrol
- PDB Entries
- 1cgz / 1dvs / 1sg0 / 1u0w / 1z1f / 2jiz / 2l98 / 2ydx / 3ckl / 3fts … show 14 more
- MSDS
- Download (16.6 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Capsule Oral Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 254 °C PhysProp - Predicted Properties
Property Value Source Water Solubility 0.0688 mg/mL ALOGPS logP 2.57 ALOGPS logP 3.4 ChemAxon logS -3.5 ALOGPS pKa (Strongest Acidic) 8.49 ChemAxon pKa (Strongest Basic) -6.2 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 60.69 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 67.46 m3·mol-1 ChemAxon Polarizability 24.55 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9952 Blood Brain Barrier + 0.59 Caco-2 permeable + 0.8915 P-glycoprotein substrate Non-substrate 0.6501 P-glycoprotein inhibitor I Non-inhibitor 0.9266 P-glycoprotein inhibitor II Non-inhibitor 0.9612 Renal organic cation transporter Non-inhibitor 0.8634 CYP450 2C9 substrate Non-substrate 0.7519 CYP450 2D6 substrate Non-substrate 0.9288 CYP450 3A4 substrate Non-substrate 0.7143 CYP450 1A2 substrate Inhibitor 0.9106 CYP450 2C9 inhibitor Inhibitor 0.7068 CYP450 2D6 inhibitor Non-inhibitor 0.9226 CYP450 2C19 inhibitor Inhibitor 0.8052 CYP450 3A4 inhibitor Inhibitor 0.7539 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8559 Ames test Non AMES toxic 0.8407 Carcinogenicity Non-carcinogens 0.7825 Biodegradation Not ready biodegradable 0.8499 Rat acute toxicity 1.6791 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8933 hERG inhibition (predictor II) Non-inhibitor 0.9462
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Stilbenes
- Sub Class
- Not Available
- Direct Parent
- Stilbenes
- Alternative Parents
- Styrenes / Resorcinols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
- Substituents
- Stilbene / Styrene / Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Benzenoid / Monocyclic benzene moiety / Organic oxygen compound / Hydrocarbon derivative
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- resveratrol (CHEBI:45713) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes, Stilbenes (C03582) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes (LMPK13090005)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Nadph dehydrogenase (quinone) activity
- Specific Function
- The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
- Gene Name
- NQO2
- Uniprot ID
- P16083
- Uniprot Name
- Ribosyldihydronicotinamide dehydrogenase [quinone]
- Molecular Weight
- 25918.4 Da
References
- Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry. 2004 Sep 14;43(36):11417-26. [PubMed:15350128]
- Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM: Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun. 2004 Oct 22;323(3):743-9. [PubMed:15381063]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Protein serine/threonine kinase activity
- Specific Function
- Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated ser...
- Gene Name
- CSNK2A1
- Uniprot ID
- P68400
- Uniprot Name
- Casein kinase II subunit alpha
- Molecular Weight
- 45143.25 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Phosphatidylinositol-4,5-bisphosphate binding
- Specific Function
- Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. Converts ...
- Gene Name
- ALOX15
- Uniprot ID
- P16050
- Uniprot Name
- Arachidonate 15-lipoxygenase
- Molecular Weight
- 74803.795 Da
References
- MacCarrone M, Lorenzon T, Guerrieri P, Agro AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34. [PubMed:10491155]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Iron ion binding
- Specific Function
- Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
- Gene Name
- ALOX5
- Uniprot ID
- P09917
- Uniprot Name
- Arachidonate 5-lipoxygenase
- Molecular Weight
- 77982.595 Da
References
- MacCarrone M, Lorenzon T, Guerrieri P, Agro AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34. [PubMed:10491155]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Transcription regulatory region dna binding
- Specific Function
- Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
- Gene Name
- AHR
- Uniprot ID
- P35869
- Uniprot Name
- Aryl hydrocarbon receptor
- Molecular Weight
- 96146.705 Da
References
- de Medina P, Casper R, Savouret JF, Poirot M: Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators. J Med Chem. 2005 Jan 13;48(1):287-91. [PubMed:15634023]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Together with PI4K2A and the type III PI4Ks (PIK4CA and PIK4CB) it contributes to the overall PI4-kinase activity of the cell. This contribution may be especially significant in plasma membrane, endosomal and Golgi compartments. The phosphorylation of phosphatidylinositol (PI) to PI4P is the first committed step in the generation of phosphatidylinositol 4,5-bisphosphate (PIP2), a precursor of the second messenger inositol 1,4,5-trisphosphate (InsP3). Contributes to the production of InsP3 in stimulated cells and is likely to be involved in the regulation of vesicular trafficking.
- Specific Function
- 1-phosphatidylinositol 4-kinase activity
- Gene Name
- PI4K2B
- Uniprot ID
- Q8TCG2
- Uniprot Name
- Phosphatidylinositol 4-kinase type 2-beta
- Molecular Weight
- 54743.71 Da
References
- Srivastava R, Ratheesh A, Gude RK, Rao KV, Panda D, Subrahmanyam G: Resveratrol inhibits type II phosphatidylinositol 4-kinase: a key component in pathways of phosphoinositide turn over. Biochem Pharmacol. 2005 Oct 1;70(7):1048-55. [PubMed:16102733]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Integrin alpha-5/beta-1 is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881).
- Specific Function
- Epidermal growth factor receptor binding
- Gene Name
- ITGA5
- Uniprot ID
- P08648
- Uniprot Name
- Integrin alpha-5
- Molecular Weight
- 114535.52 Da
References
- Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY: Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer. 2013 Dec;4(6):335-42. doi: 10.1007/s12672-013-0156-8. Epub 2013 Aug 14. [PubMed:23943159]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Virus receptor activity
- Specific Function
- Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Wil...
- Gene Name
- ITGB3
- Uniprot ID
- P05106
- Uniprot Name
- Integrin beta-3
- Molecular Weight
- 87056.975 Da
References
- Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY: Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer. 2013 Dec;4(6):335-42. doi: 10.1007/s12672-013-0156-8. Epub 2013 Aug 14. [PubMed:23943159]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Transition metal ion binding
- Specific Function
- Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
- Gene Name
- APP
- Uniprot ID
- P05067
- Uniprot Name
- Amyloid beta A4 protein
- Molecular Weight
- 86942.715 Da
References
- Ahn JS, Lee JH, Kim JH, Paik SR: Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol. Anal Biochem. 2007 Aug 15;367(2):259-65. Epub 2007 May 26. [PubMed:17597573]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- SNCA
- Uniprot ID
- P37840
- Uniprot Name
- Alpha-synuclein
- Molecular Weight
- 14460.155 Da
References
- Ahn JS, Lee JH, Kim JH, Paik SR: Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol. Anal Biochem. 2007 Aug 15;367(2):259-65. Epub 2007 May 26. [PubMed:17597573]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, Forti L, Stivala LA, Iacopetta D, Dolce V, Ando S, Pezzi V, Maggiolini M: Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol Nutr Food Res. 2009 Jul;53(7):845-58. doi: 10.1002/mnfr.200800331. [PubMed:19496085]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Organic cyclic compound binding
- Specific Function
- High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
- Gene Name
- MTNR1A
- Uniprot ID
- P48039
- Uniprot Name
- Melatonin receptor type 1A
- Molecular Weight
- 39374.315 Da
References
- Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, Leclerc V, Yous S, Delagrange P, Boutin JA: Old and new inhibitors of quinone reductase 2. Chem Biol Interact. 2010 Jul 30;186(2):103-9. doi: 10.1016/j.cbi.2010.04.006. Epub 2010 May 4. [PubMed:20399199]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Melatonin receptor activity
- Specific Function
- High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
- Gene Name
- MTNR1B
- Uniprot ID
- P49286
- Uniprot Name
- Melatonin receptor type 1B
- Molecular Weight
- 40187.895 Da
References
- Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, Leclerc V, Yous S, Delagrange P, Boutin JA: Old and new inhibitors of quinone reductase 2. Chem Biol Interact. 2010 Jul 30;186(2):103-9. doi: 10.1016/j.cbi.2010.04.006. Epub 2010 May 4. [PubMed:20399199]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Carbohydrate binding
- Specific Function
- Not Available
- Gene Name
- CLEC14A
- Uniprot ID
- Q86T13
- Uniprot Name
- C-type lectin domain family 14 member A
- Molecular Weight
- 51635.005 Da
References
- Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C: Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet. 2010 Nov 15;19(22):4319-29. doi: 10.1093/hmg/ddq354. Epub 2010 Aug 20. [PubMed:20729295]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
- Gene Name
- NR1I2
- Uniprot ID
- O75469
- Uniprot Name
- Nuclear receptor subfamily 1 group I member 2
- Molecular Weight
- 49761.245 Da
References
- Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Curator comments
- Antagonist at the canonical form of the receptor. Agonist at isoform 3 of the receptor.
- General Function
- Zinc ion binding
- Specific Function
- Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
- Gene Name
- NR1I3
- Uniprot ID
- Q14994
- Uniprot Name
- Nuclear receptor subfamily 1 group I member 3
- Molecular Weight
- 39942.145 Da
References
- Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Xenobiotic transporter activity
- Specific Function
- Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
- Gene Name
- SLC2A1
- Uniprot ID
- P11166
- Uniprot Name
- Solute carrier family 2, facilitated glucose transporter member 1
- Molecular Weight
- 54083.325 Da
References
- Salas M, Obando P, Ojeda L, Ojeda P, Perez A, Vargas-Uribe M, Rivas CI, Vera JC, Reyes AM: Resolution of the direct interaction with and inhibition of the human GLUT1 hexose transporter by resveratrol from its effect on glucose accumulation. Am J Physiol Cell Physiol. 2013 Jul 1;305(1):C90-9. doi: 10.1152/ajpcell.00387.2012. Epub 2013 Apr 24. [PubMed:23615963]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- Curator comments
- Resveratrol inhibits CBR1 with a mix of competitive and non-competitive kinetics.
- General Function
- Prostaglandin-e2 9-reductase activity
- Specific Function
- NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. ...
- Gene Name
- CBR1
- Uniprot ID
- P16152
- Uniprot Name
- Carbonyl reductase [NADPH] 1
- Molecular Weight
- 30374.73 Da
References
- Ito Y, Mitani T, Harada N, Isayama A, Tanimori S, Takenaka S, Nakano Y, Inui H, Yamaji R: Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene. J Nutr Sci Vitaminol (Tokyo). 2013;59(4):358-64. [PubMed:24064738]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
- Gene Name
- PPARA
- Uniprot ID
- Q07869
- Uniprot Name
- Peroxisome proliferator-activated receptor alpha
- Molecular Weight
- 52224.595 Da
References
- Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17. [PubMed:24454499]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
- Gene Name
- PPARG
- Uniprot ID
- P37231
- Uniprot Name
- Peroxisome proliferator-activated receptor gamma
- Molecular Weight
- 57619.58 Da
References
- Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17. [PubMed:24454499]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Protein serine/threonine/tyrosine kinase activity
- Specific Function
- AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, ...
- Gene Name
- AKT1
- Uniprot ID
- P31749
- Uniprot Name
- RAC-alpha serine/threonine-protein kinase
- Molecular Weight
- 55686.035 Da
References
- Hsieh TC, Lin CY, Bennett DJ, Wu E, Wu JM: Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS One. 2014 Jun 26;9(6):e101070. doi: 10.1371/journal.pone.0101070. eCollection 2014. [PubMed:24968355]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Binds to the dendritic targeting element and may play a role in mRNA trafficking (By similarity). Part of a ternary complex that binds to the downstream control sequence (DCS) of the pre-mRNA. Mediates exon inclusion in transcripts that are subject to tissue-specific alternative splicing. May interact with single-stranded DNA from the far-upstream element (FUSE). May activate gene expression. Also involved in degradation of inherently unstable mRNAs that contain AU-rich elements (AREs) in their 3'-UTR, possibly by recruiting degradation machinery to ARE-containing mRNAs.
- Specific Function
- Dna binding
- Gene Name
- KHSRP
- Uniprot ID
- Q92945
- Uniprot Name
- Far upstream element-binding protein 2
- Molecular Weight
- 73115.16 Da
References
- Bollmann F, Art J, Henke J, Schrick K, Besche V, Bros M, Li H, Siuda D, Handler N, Bauer F, Erker T, Behnke F, Monch B, Hardle L, Hoffmann M, Chen CY, Forstermann U, Dirsch VM, Werz O, Kleinert H, Pautz A: Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity. Nucleic Acids Res. 2014 Nov 10;42(20):12555-69. doi: 10.1093/nar/gku1033. Epub 2014 Oct 28. [PubMed:25352548]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Tyrosine-trna ligase activity
- Specific Function
- Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
- Gene Name
- YARS
- Uniprot ID
- P54577
- Uniprot Name
- Tyrosine--tRNA ligase, cytoplasmic
- Molecular Weight
- 59143.025 Da
References
- Sajish M, Schimmel P: A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature. 2015 Mar 19;519(7543):370-3. doi: 10.1038/nature14028. Epub 2014 Dec 22. [PubMed:25533949]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitorInducer
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085]
- Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d 24-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A1
- Uniprot ID
- P04798
- Uniprot Name
- Cytochrome P450 1A1
- Molecular Weight
- 58164.815 Da
References
- Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
- Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1B1
- Uniprot ID
- Q16678
- Uniprot Name
- Cytochrome P450 1B1
- Molecular Weight
- 60845.33 Da
References
- Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS: Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep;3(9):1168-75. doi: 10.1158/1940-6207.CAPR-09-0155. Epub 2010 Aug 17. [PubMed:20716633]
- Piver B, Berthou F, Dreano Y, Lucas D: Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett. 2001 Dec 15;125(1-3):83-91. [PubMed:11701226]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Identical protein binding
- Specific Function
- Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
- Gene Name
- TTR
- Uniprot ID
- P02766
- Uniprot Name
- Transthyretin
- Molecular Weight
- 15886.88 Da
References
- Commodari F, Khiat A, Ibrahimi S, Brizius AR, Kalkstein N: Comparison of the phytoestrogen trans-resveratrol (3,4',5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn Reson Chem. 2005 Jul;43(7):567-72. [PubMed:15809979]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Lu Z, Zhang Y, Liu H, Yuan J, Zheng Z, Zou G: Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. J Fluoresc. 2007 Sep;17(5):580-7. Epub 2007 Jun 28. [PubMed:17597382]
Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 07:06